Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GoFast CD19 CAR T cells
- Development stage
- Phase 1
- Lead developer
- The First Medical Center of Chinese PLA General Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GoFast CD19 CAR T cells are an autologous chimeric antigen receptor (CAR) T-cell therapy developed by the Chinese PLA General Hospital. The therapy utilizes the proprietary GoFast manufacturing platform, which is designed to streamline and accelerate the production of CAR T-cells, potentially reducing the manufacturing time to approximately 24 hours. This rapid process aims to minimize the vein-to-vein time, which is critical for patients with rapidly progressing B-cell malignancies. The CAR construct is engineered to target CD19, a protein consistently expressed on the surface of B-lineage cells. Upon infusion, these engineered T cells recognize and eliminate CD19-positive malignant B cells. The therapy is currently being investigated in early-phase clinical trials for patients with relapsed or refractory B-cell lymphomas, including large B-cell lymphoma.
- Other names
- GoFast CD19 CAR-T
02
Targets
Beyond the preview
Go deeper on GoFast CD19 CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GoFast CD19 CAR T cells.